Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Atalanta Therapeutics
Research
Atalanta’s RNA epilepsy asset suppresses seizures in mice
Mice with a rare form of epilepsy given a single injection of the drug candidate had 84% fewer seizures than control mice over the next six months.
Darren Incorvaia
Apr 10, 2025 5:30am
Atalanta loads crossbow with $97M, 2 Big Pharmas in tow
Jan 28, 2025 7:00am
CRISPR Tx, Novartis, Cour & more—Chutes & Ladders
May 24, 2024 8:30am
Alcyone unveils with $23M for 12 AAV gene therapies for CNS
Jun 9, 2021 10:40am
Biogen, Genentech ally with new neurodegenerative biotech
Jan 11, 2021 9:15am
